Date: 2017-09-11
Type of information: Nomination
Compound: clinical director, head of clinical science, senior pharmaceutical physician
Company: Allergy Therapeutics (UK)
Therapeutic area: Allergic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
Financial terms:
Latest news:
- • On September 11, 2017, Allergy Therapeutics announced new senior appointments and expansion of the R&D and clinical team in line with its growth plans at its UK headquarters in Worthing. These appointments are aimed at broadening the clinical development team in order to facilitate continued progress of the pipeline and clinical development programmes, in addition to continuing to prepare for US market entry.
- The group has appointed Pieter-Jan de Kam as clinical director effective immediately. Pieter-Jan de Kam joins the Group from HAL Allergy in The Netherlands where he was responsible for clinical development, with recent successes including European and US studies for pollen and house dust mites. Prior to that, Pieter-Jan worked across Europe, in the US and in Singapore in various roles including Director of Clinical Research at Merck&Co.
- In addition to the appointment of Pieter-Jan, the Group has recruited Simon Piggott as Head of Clinical Science. He will be responsible for the delivery of the clinical strategy to facilitate progression of the group's broad pipeline and innovative technologies, working with both the established product development teams and clinical operations departments. Simon has significant experience including successful respiratory development programs through Phase I to IV having previously worked as Global Scientific Director at GSK and Associate Director at Quintiles and Vertex.
- As part of the group's continued investment in its R&D function, Tim Higenbottam has been appointed to the position of senior pharmaceutical physician and will focus on the US regulatory process, a key part of the Group's three-pillar growth strategy. The R&D team which is led by Murray Skinner, Chief Scientific Officer, has doubled the size of its headcount since 2016.
Is general: Yes
